Clinical trial NCT03490032: 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
Official title: A Phase 1/2 Open-label, Multi-center, Safety and Tolerability Study of a Single Dose of 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Prostate Cancer Metastatic
Keywords: Prostatic Neoplasms
Cancer of Prostate
Cancer of the Prostate
Neoplasms, Prostate
Prostate Cancer
Prostatic Cancer
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
PSMA
Prostate-specific membrane antigen
Gallium radioisotope 68
68Ga-PSMA-R2
68Ga-PSMA ligand
Lead sponsor: Advanced Accelerator Applications
Sponsor class: INDUSTRY
First posted: 2018-04-06
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Phase I: characterize PK and dosimetry Phase II: diagnostic potential in 2 groups

1. Prostate Cancer in biochemical relapse, and
2. Metastatic Prostate Cancer
Primary purpose: DIAGNOSTIC

Brief summary: This was an open-label, multicenter, single dose, Phase I/II study to evaluate the safety and tolerability of a single administration of 3 mega Becquerel (MBq)/kg, but not less than 150 MBq and not more than 250 MBq, of 68\^Ga-PSMA-R2 in adult male patients with biochemical relapse (BR) and metastatic prostate cancer (mPCa).

Detailed description: This study consisted of 2 parts.

* During the first part (Phase I) of the study, 6 subjects with biochemically recurrent prostate cancer (PCa) received the investigational product (IP) and remained at the site for approximately 6 hours post-administration in order to assess the PK, biodistribution versus time, and dosimetry for critical organs. Subjects received a single dose of 3 MBq/kg, (\>=150 and =\<250 MBq), of 68\^Ga-PSMA-R2 intravenously. Serial blood and urine samples were collected for PK characterization and dosimetry and whole-body PET/CT were acquired at selected time points (0 to 4 hours) to determine organ and tumor absorbed doses. Safety assessments were conducted after IP administration on Day 1, and during follow-up on Days 7 and 28.
* In the second part of the study (Phase II), 2 groups of 12 subjects were enrolled (subjects with PCa in biochemical recurrence \[PCa-BR\], and subjects with prostate cancer in the metastatic stage \[mPCa\]). Based on the preliminary data analysis from the Phase I part of the study provided sufficient dosimetry data, all subjects underwent the whole body PET/CT imaging optimized for time (up to 2 time points) according to the data analysis from the Phase I part of the study.

This study was comprised of 4 clinical visits and conducted in 3 study periods: screening, administration/imaging, and safety follow-up period.

Eligibility criteria: Inclusion Criteria:

1. Males 18 years or older.
2. Signed and dated written informed consent by the subject prior to any study-specific procedures.
3. Histologically confirmed adenocarcinoma of the prostate, defined as follows:

   1. Biochemical recurrence: defined as PSA is ≥0.2 ng/mL after radical prostatectomy or PSA nadir plus 2 ng/mL after radiation therapy with corresponding CT/MRI or bone scan revealing absence of local recurrence or metastatic lesions.

      OR
   2. Metastatic disease: defined as both, castration-sensitive or castration-resistant mPCa (presence of at least 1 metastatic lymph node, visceral metastasis and/or bone metastasis).
   3. At least 2 weeks must have elapsed between last anticancer treatment administration and the administration of the imaging product, 68Ga-PSMA-R2.
4. Prior major surgery must be at least 12 weeks prior to study entry.
5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2, with a life expectancy ≥6 months.
6. Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at Screening:

   1. Hemoglobin (Hb): \>8 g/dL
   2. Platelet count of \>50.000/mm3
7. Serum creatinine \<1.5\*upper limit normal (ULN) or estimated glomerular filtration rate (eGFR) \>50 mL/min based upon The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
8. For male subjects with partners of childbearing potential, agreement to use barrier contraceptive method (condom) and to continue its use for 28 days after IP administration.

Exclusion Criteria:

1. Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate or any other histologies different than adenocarcinoma.
2. Administered a radioisotope =\<10 physical half-lives prior to the day of PET/CT.
3. Current severe urinary incontinence, hydronephrosis, severe voiding dysfunction, or need of indwelling/condom catheters.
4. Uncontrolled pain or incompatibility that results in subject's lack of compliance with imaging procedures.
5. Other known coexisting malignancies except non-melanoma skin or low grade superficial bladder cancer unless definitively treated and proven no evidence of recurrence for 5 years.
6. Subject with known incompatibility to CT scans.
7. Any evidence of severe or uncontrolled systemic or psychiatric diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the protocol, or active infection including human immunodeficiency virus (HIV) and untreated hepatitis B, hepatitis C. Screening for chronic conditions was not required.
8. Subjects who have received any investigational agent within the last 28 days were excluded from participation in this study.
9. Any acute toxicity due to prior chemotherapy and/or radiotherapy that has not resolved according to the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Studies.
10. Known allergy, hypersensitivity, or intolerance to the IP or its excipients.
11. Subject unlikely to comply with study procedures, restrictions and requirements and judged by the investigator to be unsuitable for study participation.

Primary outcomes:
measure: Number of Participants With Treatment Emergent Adverse Events
timeFrame: dosing through 28 days post-dose
Secondary outcomes:
measure: Phase I: Decay Corrected Tissue Time-activity Curves (TACs) From 68Ga-PSMA-R2 PET/CT Images in Normal Organs
timeFrame: 68Ga-PSMA-R2 PET imaging acquired at Day 1 (20-30 min post-injection, 1 hour, 2 hours and 3-4 hours post-injection)
measure: Phase I: Urinary Excretion of [68Ga]-PSMA-R2
timeFrame: 0 to 6 hours post-dose
measure: Phase I: Half-life of 68Ga-PSMA-R2 in Blood
timeFrame: 0 to 6 hours post-dose
measure: Phase I: Non-decay Corrected Tissue Time-activity Curves (TACs) From 68Ga-PSMA-R2 PET/CT Images in Normal Organs
timeFrame: 68Ga-PSMA-R2 PET imaging acquired at Day 1 (20-30 min post-injection, 1 hour, 2 hours and 3-4 hours post-injection)
measure: Phase I: Residence Times in Normal Organs
timeFrame: 68Ga-PSMA-R2 PET imaging acquired at Day 1
measure: Phase I: Absorbed Dose of 68Ga-PSMA-R2
timeFrame: 68Ga-PSMA-R2 PET imaging acquired at Day 1
measure: Phase I: Whole-body Dose of 68Ga-PSMA-R2
timeFrame: 68Ga-PSMA-R2 PET imaging acquired at Day 1
measure: Phase I: Effective Dose of 68Ga-PSMA-R2
timeFrame: 68Ga-PSMA-R2 PET imaging acquired at Day 1
measure: Standard Uptake Value (SUV) Mean and Max in Lesions Detected by PET Scans by Timepoint
timeFrame: 68Ga-PSMA-R2 PET imaging acquired at Day 1 (1 hour, 2 hours post-injection)
measure: Tumor to Background Ratio (TBR) of Lesions Detected by PET Scans by Timepoint
timeFrame: 68Ga-PSMA-R2 PET imaging acquired at Day 1 (1 hour, 2 hours post-injection)
measure: Standard Uptake Value (SUV) Mean and Max in Lesions Detected by PET Scans and Also Detected by Conventional Scans by Timepoint
timeFrame: 68Ga-PSMA-R2 PET imaging acquired at Day 1 (1 hour, 2 hours post-injection)
measure: Tumor to Background Ratio (TBR) of Lesions Detected by PET Scans and Also Detected by Conventional Scans by Timepoint
timeFrame: 68Ga-PSMA-R2 PET imaging acquired at Day 1 (1 hour, 2 hours post-injection)
measure: Standard Uptake Value (SUV) Mean and Max in Lesions Detected by PET Scans and Not Detected by Conventional Scans by Timepoint
timeFrame: 68Ga-PSMA-R2 PET imaging acquired at Day 1 (1 hour, 2 hours post-injection)
measure: Tumor to Background Ratio (TBR) of Lesions Detected by PET Scans and Not Detected by Conventional Scans by Timepoint
timeFrame: 68Ga-PSMA-R2 PET imaging acquired at Day 1 (1 hour, 2 hours post-injection)
measure: Patient Level Agreement of 68Ga-PSMA-R2 PET Imaging Relative to Conventional Techniques in Prostate Cancer Patients
timeFrame: 68Ga-PSMA-R2 PET imaging acquired at Day 1 (1 hour, 2 hours post-injection)
measure: Burden of Tumor Lesions Measured by 68Ga-PSMA-R2 PET (1hr) Scan Compared With Standard Imaging Modality, by Location (Overall)
timeFrame: 68Ga-PSMA-R2 PET imaging acquired at Day 1 (1 hour post-injection)
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Pheonix Molecular Imaging Center
state: Arizona
city: San Francisco
country: United States
facility: University of California, San Francisco (UCSF)
state: California
city: New Haven
country: United States
facility: Smilow Cancer Center at Yale New Haven
state: Connecticut
city: Baltimore
country: United States
facility: Johns Hopkins Hospital
state: Maryland
city: Bethesda
country: United States
facility: National Institutes of Health, Warren Grant Magnusen Clinical Center
state: Maryland
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References: